Evicenter
MarkdownMedical informationP&T meetings
Claseprubart (DNTH103)

Generalized myasthenia gravis

Launch
Not announced
Last updated
120 sources

Section 4 of 6

Clinical evidence

182 evidence topics · 37 sources

Study summaries

EMERGE

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using MG-ADL as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Planned participants per arm in the November 2026 corporate deck
Description of analysis sets

No evidence found.

Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations
Summary

EMERGE began on 2026-06-29 and has reported no efficacy or safety results; the company expects top-line results in the second half of 2028, and a company presentation lists updated EMERGE top-line guidance by the end of 2027. Enrollment is limited to approximately 195 adults aged 18 to 80 years who are acetylcholine receptor antibody positive, with an MG-ADL score of 6 or more and a QMG score of 10 or more, so participants with anti-MuSK, anti-LRP4, or seronegative generalized myasthenia gravis are not represented. The randomized, placebo-controlled period lasts 17 weeks, and longer-term data will come from an optional 104-week extended treatment period that includes an open-label extension.

MaGic

Objective
Location and study date
Study dates and status in the ClinicalTrials.gov record
FieldQuoted record
Recruitment status“Active, not recruiting”
Study start (actual)“2024-02-23”
Primary completion (actual)“2025-07-28”
Study completion (estimated)“2028-10”
First posted“2024-02-28”
Last update posted“2026-07-27”
Study design
Design details in the ClinicalTrials.gov record
FieldQuoted record
Study type“Interventional”
Phase“Phase 2”
Primary purpose“Treatment”
Allocation“Randomized”
Interventional model“Parallel Assignment”
Masking“Quadruple”
Eligibility criteria
Treatment
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Participants analyzed for MG-ADL minimal symptom expression at week 13
ArmParticipants achieving MG-ADL MSE / analyzed
Placebo“3/22”
Claseprubart 300 mg Q2W“7/19”
Claseprubart 600 mg Q2W“6/22”
Description of analysis sets
Results
Participant disposition
Completion of the randomized controlled period and discontinuations by arm
MeasurePlacebo (n=22)Claseprubart 300 mg Q2W (n=21)Claseprubart 600 mg Q2W (n=22)
Study discontinuations, n (%)“1 (4.5)”“1 (4.8)”“0 (0)”
Due to AE, n (%)“0 (0)”“0 (0)”“0 (0)”
Baseline characteristics
Demographic and disease characteristics by arm
CharacteristicPlacebo (N=22)Claseprubart 300 mg Q2W (N=21)Claseprubart 600 mg Q2W (N=22)
Age, mean (SD), years“52.2 (16.5)”“57.1 (13.7)”“55.3 (12.0)”
Male, n (%)“13 (59%)”“14 (67%)”“10 (45%)”
Weight, mean (SD), pounds“195.0 (48.0)”“192.5 (35.5)”“179.0 (35.4)”
Duration of disease, median (range), years“7.7 (0.4 – 21.2)”“3.0 (0.5 – 22.1)”“7.6 (1.0 – 37.3)”
MG-ADL score at baseline, mean (SD)“8.5 (2.9)”“8.2 (2.2)”“8.4 (2.6)”
QMG score at baseline, mean (SD)“14.2 (5.8)”“12.2 (2.7)”“12.2 (3.6)”
MG Composite score at baseline, mean (SD)“15.0 (7.8)”“16.3 (4.5)”“16.0 (5.3)”
MG-QoL-15r score at baseline, mean (SD)“14.3 (7.0)”“15.4 (6.6)”“14.9 (5.9)”
MGFA class II at screening, n (%)“7 (32%)”“11 (52%)”“12 (55%)”
MGFA class III at screening, n (%)“12 (55%)”“10 (48%)”“9 (41%)”
MGFA class IVa at screening, n (%)“3 (14%)”“0 (0%)”“1 (5%)”
Prior thymectomy, n (%)“8 (36%)”“6 (29%)”“7 (32%)”
Baseline corticosteroid use, n (%)“19 (86%)”“17 (81%)”“20 (91%)”
One immunosuppressive therapy at baseline, n (%)“11 (50%)”“10 (48%)”“12 (55%)”
More than one immunosuppressive therapy at baseline, n (%)“11 (50%)”“11 (52%)”“10 (45%)”
FcRn use in prior 24 months, n (%)“0 (0%)”“1 (5%)”“0 (0%)”
Prior complement use, n (%)“0 (0%)”“0 (0%)”“0 (0%)”
Efficacy results
Week 13 efficacy summary by arm with placebo-adjusted differences
Measure at week 13Placebo (N=22)Claseprubart 300 mg Q2W (N=21), absoluteClaseprubart 300 mg Q2W, placebo-adjusted (one-sided P)Claseprubart 600 mg Q2W (N=22), absoluteClaseprubart 600 mg Q2W, placebo-adjusted (one-sided P)
MG-ADL mean change from baseline“-2.8”“-4.6”“-1.8 (P=0.0113)”“-5.4”“-2.6 (P=0.0006)”
QMG mean change from baseline“-2.0”“-4.4”“-2.4 (P=0.0144)”“-4.5”“-2.5 (P=0.0111)”
MSE“14%”“37%”“23% (P=0.0550)”“27%”“13% (P=0.1031)”
MGC mean change from baseline“-3.1”“-8.7”“-5.6 (P=0.0008)”“-8.6”“-5.5 (P=0.0008)”
Two-sided P values for MG-ADL and QMG at week 13
MeasureClaseprubart 300 mg Q2W vs placebo, two-sided PClaseprubart 600 mg Q2W vs placebo, two-sided P
MG-ADL“P=0.0227”“P=0.0013”
QMG“P=0.0288”“P=0.0222”
Health-related quality of life and patient-reported outcomes
MG-QoL-15r change from baseline at week 13 by arm with placebo-adjusted differences
Measure at week 13Placebo (N=22)Claseprubart 300 mg Q2W (N=21), absoluteClaseprubart 300 mg Q2W, placebo-adjusted (one-sided P)Claseprubart 600 mg Q2W (N=22), absoluteClaseprubart 600 mg Q2W, placebo-adjusted (one-sided P)
MG-QoL-15r mean change from baseline“-3.9”“-6.1”“-2.2 (P=0.0414)”“-5.4”“-1.5 (P=0.1122)”
Safety results
Safety and tolerability during the 13-week randomized controlled period
Event, n (%)Placebo (n=22)Claseprubart 300 mg Q2W (n=21)Claseprubart 600 mg Q2W (n=22)
Any treatment-related AEs“13 (59.1)”“15 (71.4)”“21 (95.5)”
Clinical AEs“11 (50.0%)”“13 (61.9%)”“15 (68.2%)”
Treatment-related serious AEs“1 (4.5%)”“0 (0%)”“0 (0%)”
Infections“10 (45.5%)”“5 (23.8%)”“6 (27.3%)”
Treatment-related serious infections“1 (4.5%)”“0 (0%)”“0 (0%)”
Injection site reactions“0 (0%)”“2 (9.5%)”“2 (9.1%)”
Newly positive for ANA“0 (0%)”“1 (5.9%)”“8 (36.4%)”
Rashes“0 (0%)”“0 (0%)”“0 (0%)”
Arthralgia“1 (4.5%)”“1 (4.8%)”“0 (0%)”
Discontinuation due to related adverse events in the randomized controlled period
Event, n (%)Placebo (N=22)Claseprubart 300 mg Q2W (n=21)Claseprubart 600 mg Q2W (n=22)
RCT discontinuation due to related AE“0 (0%)”“0 (0%)”“0 (0%)”
Most common adverse events in more than 5% of participants in any arm
Adverse event, n (%)Placebo (N=22)Claseprubart 300 mg Q2W (n=21)Claseprubart 600 mg Q2W (n=22)
Nasopharyngitis“1 (4.5)”“3 (14.3%)”“3 (13.6)”
Lipase increased“0 (0%)”“3 (14.3%)”“2 (9.1%)”
Upper respiratory tract infection“3 (13.6%)”“0 (0%)”“1 (4.5%)”
Sinusitis“2 (9.1%)”“0 (0%)”“0 (0%)”
Headache“2 (9.1%)”“0 (0%)”“0 (0%)”
Diarrhea“2 (9.1%)”“0 (0%)”“0 (0%)”
Myasthenia gravis exacerbations in the randomized controlled period
Event, n (%)Placebo (N=22)Claseprubart 300 mg Q2W (n=21)Claseprubart 600 mg Q2W (n=22)
Myasthenia gravis exacerbations“2 (9.1%)”“2 (9.5%)”“2 (9.1%)”
Open-label extension: adverse events through 52 weeks compared with the randomized controlled period
Adverse event, n (%)Randomized period: placebo (n=22)Randomized period: pooled claseprubart (n=43)Open-label extension: all claseprubart (n=60)
Clinical AEs“11 (50.0)”“28 (65.1)”“45 (75.0)”
Related serious AEs“1 (4.5)”“0 (0.0)”“1 (1.7)”
Discontinuation due to related AE“0 (0)”“0 (0)”“1 (1.7)”
Infections“10 (45.5)”“11 (25.6)”“28 (46.7)”
Related serious infections“1 (4.5)”“0 (0)”“1 (1.7)”
Injection site reaction“0 (0)”“4 (9.3)”“1 (1.7)”
Arthralgia“1 (4.5)”“1 (1.7)”“4 (6.7)”
Myasthenia gravis exacerbation“2 (9.1)”“4 (9.3)”“7 (11.7)”
Study limitations
Summary

MaGic is a phase 2 trial in which 65 participants with acetylcholine receptor antibody-positive generalized myasthenia gravis were randomized 1:1:1 to claseprubart 300 mg every 2 weeks (21 participants), claseprubart 600 mg every 2 weeks (22 participants), or placebo (22 participants) for 13 weeks. The primary endpoint was safety and tolerability, measured as the incidence of treatment-emergent adverse events and serious adverse events to week 13; MG-ADL, QMG, and MGC were secondary endpoints, and minimal symptom expression and MG-QoL-15r were exploratory. Efficacy comparisons with placebo used one-sided P values, with values below 0.1 considered nominally significant, the MG-ADL result in participants with a baseline QMG score of 10 or higher came from a post hoc analysis of 18 and 16 participants, and the open-label extension pooled both dose groups without a placebo comparison after week 13. The results reported through November 2026 appear in company press releases and presentations and in congress posters and abstracts, and no peer-reviewed full article reporting the trial was identified.

DNTH103-AU-001

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics

No evidence found.

Efficacy results
Part C pharmacokinetics after immunoglobulin G

No evidence found.

Health-related quality of life and patient-reported outcomes

Not applicable.

Safety results
Part C safety

No evidence found.

Study limitations
Summary

DNTH103-AU-001 enrolled healthy adults aged 18 to 65 years and excluded people with a history of autoimmune disease, so its safety, pharmacokinetic, and pharmacodynamic findings come from a population without the diseases claseprubart is being developed to treat, and the company states that the same results may not be seen in patients in later trials. Each dose cohort was planned with 8 participants (6 receiving DNTH103 and 2 receiving placebo); the company reported 52 healthy volunteers in seven cohorts in its top-line announcement and 60 healthy volunteers in eight cohorts who completed dosing as of December 2023, while the registry records a final accrual of 68 for Parts A and B and 9 for the open-label, uncontrolled Part C. The ACTRN12622001265763 record lists recruitment in Christchurch, New Zealand, and neither registry record has uploaded results documents, so the available results come from company press releases, presentations, and annual reports, and no Part C result has been reported. The company states that FDA acceptance of data from trials conducted outside the United States is subject to conditions the FDA imposes.